Patient Reported Outcomes in Pulmonary Arterial Hypertension
NCT01792622
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Evidence of a personally signed and dated informed consent
- Subjects aged >=18 who have documented PAH
- Speak English
- Subjects who provide written informed consent to participate in the study before being screened for the study.
- Patients with non-PAH Pulmonary Hypertension
- Physical inability to complete the interview process
- Subjects who are currently enrolled in an experimental drug study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Hyderabad, Andra Pradesh
- Ahmedabad, Gujarat
- Vadodara, Gujarat
- Bangalore, Karnataka
- Noida, Uttar Pradesh
- Los Angeles, California
- Detroit, Michigan
- Pittsburgh, Pennsylvania
- Houston, Texas
- Houston, Texas
- San Antonio, Texas
- Darlinghurst, New South Wales
- Chermside, Queensland
- Praha 2,
- Praha 4,
- Lille,
- Lille,
- Vandoeuvre Les Nancy,
- Berlin,
- Coburg,
- Essen,
- Giessen,
- Hannover,
- Homburg,
- Leipzig,
- Muenchen,
- Nuernberg,
- Wuerzburg,
- Haidari, Athens
- Haifa,
- Petach Tikva,
- Napoli,
- Roma,
- Taipei,
- Papworth Everard, Cambridgeshire
- Phoenix, Arizona
- Augusta, Georgia
- Decatur, Georgia
- Elk Grove Village, Illinois
- Indianapolis, Indiana
- Chapel Hill, North Carolina
- Charlotte, North Carolina
- Charlotte, North Carolina
- Houston, Texas
- Houston, Texas
- Salt Lake City, Utah
- Richmond, Virginia
- Richmond, Virginia
- Richmond, Virginia
- Richmond, Virginia
- Leuven,
- Porto Alegre, RS
- Sao Paulo, SP
- Sofia,
- Sofia,
- Beijing,
- Shanghai,
- Haidari, Athens
- Hyderabad, Andhra Pradesh
- Ahmedabad, Gujarat
- Vadodara, Gujarat
- Bangalore, Karnataka
- Noida, Uttar Pradesh
- Pavia,
- Roma,
- Riga,
- Kuala Lumpur,
- Amsterdam,
- Rotterdam,
- Manila City,
- Quezon City,
- Krakow,
- Zabrze,
- Timisoara, Timis
- Iasi,
- Moscow,
- Moscow,
- Amphoe Mueang, Khon Kaen
- Bangkok,
- Norwich, Norfolk
- Newcastle Upon Tyne, Tyne and Wear
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | Patient Reported Outcomes in Pulmonary Arterial Hypertension | |||
Official Title | Patient Reported Outcomes in Pulmonary Arterial Hypertension | |||
Brief Summary | Develop a brief, new, patient reported outcome instrument that is valid for use in clinical practice and clinical trials. | |||
Detailed Description | This study will use the Clinical Impact Method to develop a patient reported outcome for use in patients with pulmonary arterial hypertension Clinical personnel at the study sites will approach and discuss possible participation in Phase I and II of the study with subjects from the existing pool of patients currently receiving usual and customary care at the site. | |||
Study Type | Observational | |||
Study Design | Observational Model: Other Time Perspective: Prospective | |||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | Patients with pulmonary arterial hypertension | |||
Condition | Pulmonary Arterial Hypertension | |||
Intervention |
| |||
Study Groups/Cohorts |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status | Withdrawn | |||
Actual Enrollment | 0 | |||
Original Estimated Enrollment | 220 | |||
Estimated Study Completion Date | September 2013 | |||
Estimated Primary Completion Date | September 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender |
| |||
Ages | 18 Years to 100 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT01792622 | |||
Other Study ID Numbers | A1481296 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators |
| |||
Investigators |
| |||
PRS Account | Pfizer | |||
Verification Date | January 2021 |